Vicriviroc - Merck & Co.

Drug Profile

Vicriviroc - Merck & Co.

Alternative Names: MK-7690; SCH-417; SCH-417690; SCH-D; Schering-D

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antineoplastics; Antiretrovirals; Piperazines; Pyrimidines
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Discontinued HIV-1 infections

Most Recent Events

  • 24 Sep 2018 Phase-II clinical trials in Colorectal cancer (Combination therapy) in USA (PO)
  • 15 Aug 2018 Merck Sharp & Dohme plans a phase II trial for Colorectal cancer (Second-line therapy or greater; Late-stage disease) in September 2018 , (NCT03631407)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top